Literature DB >> 30324293

Out-of-pocket Spending on Orphan Drug Prescriptions Among Commercially Insured Adults in 2014.

Kao-Ping Chua1, Rena M Conti2,3.   

Abstract

Mesh：

Year:  2019        PMID： 30324293      PMCID： PMC6420515          DOI： 10.1007/s11606-018-4694-1

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN： 0884-8734            Impact factor:   5.128


× No keyword cloud information.
  4 in total

1.  The impact of the Orphan Drug Act on Food and Drug Administration-approved therapies for rare skin diseases and skin-related cancers.

Authors:  Laura Karas; Christine Y Lu; Pankaj B Agrawal; Maryam M Asgari
Journal:  J Am Acad Dermatol       Date:  2019-05-16       Impact factor: 11.527

2.  Orphan Drugs Offer Larger Health Gains but Less Favorable Cost-effectiveness than Non-orphan Drugs.

Authors:  James D Chambers; Madison C Silver; Flora C Berklein; Joshua T Cohen; Peter J Neumann
Journal:  J Gen Intern Med       Date:  2020-04-13       Impact factor: 5.128

3.  Pediatric Orphan Drug Indications: 2010-2018.

Authors:  Lauren Kimmel; Rena M Conti; Anna Volerman; Kao-Ping Chua
Journal:  Pediatrics       Date:  2020-03-03       Impact factor: 7.124

4.  Spending For Orphan Indications Among Top-Selling Orphan Drugs Approved To Treat Common Diseases.

Authors:  Kao-Ping Chua; Lauren E Kimmel; Rena M Conti
Journal:  Health Aff (Millwood)       Date:  2021-03       Impact factor: 6.301
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.